Ehimare Akhabue1, Thanh-Huyen T Vu2, Anand Vaidya3, Erin D Michos4, Ian H de Boer5, Bryan Kestenbaum5, Matthew Allison6, Moyses Szklo7, Pamela Ouyang4, Clyde W Yancy8, Myles Wolf9, Tamara Isakova10, Mercedes R Carnethon2. 1. Division of Cardiovascular Diseases and Hypertension, Department of Medicine, Rutgers University Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA. 2. Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. 3. Division of Endocrinology, Diabetes and Hypertension, Harvard Medical School, Boston, Massachusetts, USA. 4. Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 5. Division of Nephrology, University of Washington School of Medicine, Seattle, Washington, USA. 6. Division of Preventive Medicine, University of California-San Diego School of Medicine, La Jolla, California, USA. 7. Division of Cardiovascular and Clinical Epidemiology, John Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. 8. Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. 9. Division of Nephrology, Duke University School of Medicine, Durham, North Carolin, USA. 10. Division of Nephrology and Hypertension, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Abstract
BACKGROUND: Higher fibroblast growth factor-23 (FGF23) concentrations have been found to be associated with incident heart failure (HF). Experimental data suggest FGF23 directly stimulates myocardial hypertrophy. FGF23 may also enhance renin-angiotensin-aldosterone system activity. Whether FGF23 is associated with increased HF risk in populations with hypertension and whether this association is weaker in the presence of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) therapy is unknown. METHODS: We studied 2,858 adults with hypertension free of cardiovascular disease at baseline (65.6 ± 9.5 years, 46.2% male) participating in the Multi-Ethnic Study of Atherosclerosis (MESA). We investigated the association of baseline serum intact FGF23 with incident HF over a 14-year median follow-up and whether ACEI/ARB therapy modified this risk. We also investigated the relationship of FGF23 with aldosterone and plasma renin activity in a random subgroup of the entire MESA cohort with available assays (N = 1,642). RESULTS: In adjusted Cox regression models, higher FGF23 was associated with a 63% greater hazard of incident HF (hazard ratio: 1.63, 95% confidence interval: [1.13-2.36] per 1-unit increase in log-transformed FGF23), which persisted after exclusion of participants with chronic kidney disease (hazard ratio: 1.94 [1.10-3.43]). There was no heterogeneity by ACEI/ARB use (Pinteraction = 0.438). FGF23 improved model fit over covariables (likelihood ratio χ2 = 6.67, P = 0.010). In multivariable linear regression models, there was no association between FGF23 and aldosterone or plasma renin activity. CONCLUSIONS: Higher FGF23 concentrations are associated with a significantly increased risk of HF in hypertension but this risk did not differ by ACEI/ARB treatment status. FGF23 may be a useful biomarker for HF risk in hypertensive populations.
BACKGROUND: Higher fibroblast growth factor-23 (FGF23) concentrations have been found to be associated with incident heart failure (HF). Experimental data suggest FGF23 directly stimulates myocardial hypertrophy. FGF23 may also enhance renin-angiotensin-aldosterone system activity. Whether FGF23 is associated with increased HF risk in populations with hypertension and whether this association is weaker in the presence of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) therapy is unknown. METHODS: We studied 2,858 adults with hypertension free of cardiovascular disease at baseline (65.6 ± 9.5 years, 46.2% male) participating in the Multi-Ethnic Study of Atherosclerosis (MESA). We investigated the association of baseline serum intact FGF23 with incident HF over a 14-year median follow-up and whether ACEI/ARB therapy modified this risk. We also investigated the relationship of FGF23 with aldosterone and plasma renin activity in a random subgroup of the entire MESA cohort with available assays (N = 1,642). RESULTS: In adjusted Cox regression models, higher FGF23 was associated with a 63% greater hazard of incident HF (hazard ratio: 1.63, 95% confidence interval: [1.13-2.36] per 1-unit increase in log-transformed FGF23), which persisted after exclusion of participants with chronic kidney disease (hazard ratio: 1.94 [1.10-3.43]). There was no heterogeneity by ACEI/ARB use (Pinteraction = 0.438). FGF23 improved model fit over covariables (likelihood ratio χ2 = 6.67, P = 0.010). In multivariable linear regression models, there was no association between FGF23 and aldosterone or plasma renin activity. CONCLUSIONS: Higher FGF23 concentrations are associated with a significantly increased risk of HF in hypertension but this risk did not differ by ACEI/ARB treatment status. FGF23 may be a useful biomarker for HF risk in hypertensive populations.
Authors: Tamara Isakova; Huiliang Xie; Wei Yang; Dawei Xie; Amanda Hyre Anderson; Julia Scialla; Patricia Wahl; Orlando M Gutiérrez; Susan Steigerwalt; Jiang He; Stanley Schwartz; Joan Lo; Akinlolu Ojo; James Sondheimer; Chi-yuan Hsu; James Lash; Mary Leonard; John W Kusek; Harold I Feldman; Myles Wolf Journal: JAMA Date: 2011-06-15 Impact factor: 56.272
Authors: Julia J Scialla; Huiliang Xie; Mahboob Rahman; Amanda Hyre Anderson; Tamara Isakova; Akinlolu Ojo; Xiaoming Zhang; Lisa Nessel; Takayuki Hamano; Juan E Grunwald; Dominic S Raj; Wei Yang; Jiang He; James P Lash; Alan S Go; John W Kusek; Harold Feldman; Myles Wolf Journal: J Am Soc Nephrol Date: 2013-10-24 Impact factor: 10.121
Authors: Michael A Crackower; Renu Sarao; Gavin Y Oudit; Chana Yagil; Ivona Kozieradzki; Sam E Scanga; Antonio J Oliveira-dos-Santos; Joan da Costa; Liyong Zhang; York Pei; James Scholey; Carlos M Ferrario; Armen S Manoukian; Mark C Chappell; Peter H Backx; Yoram Yagil; Josef M Penninger Journal: Nature Date: 2002-06-20 Impact factor: 49.962
Authors: Jacob A Udell; David A Morrow; Petr Jarolim; Sarah Sloan; Elaine B Hoffman; Thomas F O'Donnell; Amit N Vora; Torbjørn Omland; Scott D Solomon; Marc A Pfeffer; Eugene Braunwald; Marc S Sabatine Journal: J Am Coll Cardiol Date: 2014-04-09 Impact factor: 24.094
Authors: Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy Journal: Am J Epidemiol Date: 2002-11-01 Impact factor: 4.897
Authors: C R Benedict; D E Johnstone; D H Weiner; M G Bourassa; V Bittner; R Kay; P Kirlin; B Greenberg; R M Kohn; J M Nicklas Journal: J Am Coll Cardiol Date: 1994-05 Impact factor: 24.094
Authors: Matthias B Moor; Nasser A Dhayat; Simeon Schietzel; Michael Grössl; Bruno Vogt; Daniel G Fuster Journal: Urolithiasis Date: 2022-02-24 Impact factor: 2.861
Authors: Katharina Dörr; Michael Kammer; Roman Reindl-Schwaighofer; Matthias Lorenz; Rodrig Marculescu; Marko Poglitsch; Dietrich Beitzke; Rainer Oberbauer Journal: Front Med (Lausanne) Date: 2022-04-26